

MARKET REPORT



Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023

Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023

Summary

The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and daratumumab, which will not only provide a new treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Furthermore, the relatively mild safety profile of these mAbs and the significant efficacies demonstrated by these agents will mean that more MM patients will ultimately receive drug treatment. Label extensions of these mAbs, as well as of second-generation proteasome inhibitors ixazomib and Kyprolis, will further increase treatment options for these patients. The biggest constrainers of the MM market are the increasing cost-consciousness of healthcare providers, as the launch and subsequent label extensions of these pipeline agents will lead to a significant expense, which may impact uptake of these drugs. The patent expiries of Revlimid and Velcade will somewhat alleviate healthcare spending on multiple myeloma patients, which may assist in the uptake of mAbs and second-generation PIs in the multiple myeloma market.

The 5EU market is forecast to show a larger increase in size. This is due to the launch of premium priced Kyprolis, Empliciti, and daratumumab, as well as the later launch of Revlimid and Velcade generics, compared to the US.

Scope

- Overview of Multiple Myeloma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Multiple Myeloma market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Multiple Myeloma.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in 5EU.

Additional Details

Publisher : Global Data
Reference : GDHC307CFR
Number of Pages : 175
Report Format : PDF
Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023 [Published by Global Data]

- 1 Table of Contents1 Table of Contents 21.1 List of Tables 61.2 List of Figures 102 Introduction 112.1 Catalyst 112.2 Related Reports 122.3 Upcoming Related Reports 123 Disease Overview 133.1 Etiology and Pathophysiology 133.1.1 Etiology 133.1.2 Pathophysiology 133.2 Staging Systems 163.3 Response and Relapse Criteria 173.4 Symptoms 193.5 Prognosis 203.6 Quality of Life 214 Disease Management 244.1 Treatment Overview 244.2 Diagnosis 254.3 Clinical Practice 264.3.1 Primary Therapy for SCT-Eligible Patients 274.3.2 Primary Therapy for Non-SCT Patients 294.3.3 Salvage/Relapse Therapy 304.3.4 Leading Prescribed Drugs 314.4 France 344.4.1 Diagnosis 354.4.2 Clinical Practice 364.5 Germany 364.5.1 Diagnosis 384.5.2 Clinical Practice 384.6 Italy 394.6.1 Diagnosis 404.6.2 Clinical Practice 404.7 Spain 424.7.1 Diagnosis 434.7.2 Clinical Practice 434.8 UK 444.8.1 Diagnosis 454.8.2 Clinical Practice 465 Competitive Assessment 475.1 Overview 475.2 Product Profiles - Proteasome Inhibitors 475.2.1 Velcade (Bortezomib) 475.2.2 Kyprolis (Carfilzomib) 545.3 Product Profiles - Immunomodulators 625.3.1 Revlimid (Lenalidomide) 625.3.2 Pomalyst/Imnovid (Pomalidomide) 695.4 Other Therapeutic Classes 746 Unmet Need and Opportunity 756.1 Overview 756.2 Treatment of High-Risk Patients 756.2.1 Unmet Need 756.2.2 Gap Analysis 766.2.3 Opportunity 776.3 Treatment of Patients with Smoldering Myeloma 776.3.1 Unmet Need 776.3.2 Gap Analysis 796.3.3 Opportunity 796.4 Treatment of Extramedullary Disease 806.4.1 Unmet Need 806.4.2 Gap Analysis 806.4.3 Opportunity 817 Pipeline Assessment 827.1 Overview 827.2 Promising Drugs in Clinical Development 827.2.1 Farydak (Panobinostat) 827.2.2 Ixazomib 897.2.3 Empliciti (Elotuzumab) 947.2.4 Daratumumab 1007.2.5 Aplidin (Plitidepsin) 1057.3 Promising Drugs in Early-Stage Development 1097.3.1 Oprozomib (ONX-0912) 1097.3.2 Filanesib 1107.3.3 SAR650984 1107.3.4 Marizomib 1127.3.5 Evofosfamide 1127.3.6 LGH447 1137.3.7 Selinexor (KPT-330) 1138 Market Outlook 1158.1 5EU 1158.1.1 Forecast 1158.1.2 Key Events 1198.1.3 Drivers - 5EU 1198.1.4 Barriers - 5EU 1219 Appendix 1249.1 Bibliography 1249.2 Abbreviations 1469.3 Methodology 1509.4 Forecasting Methodology 1509.4.1 Diagnosed Multiple Myeloma Patients 1509.4.2 Percent of Drug-Treated Patients 1519.4.3 Drugs Included in Each Therapeutic Class 1519.4.4 Launch and Patent Expiry Dates 1529.4.5 General Pricing Assumptions 1539.4.6 Individual Drug Assumptions 1549.4.7 Pricing of Pipeline Agents 1619.4.8 Generic Erosion 1689.5 Primary Research - KOLs Interviewed for this Report 1699.6 Primary Research - High-Prescriber Survey 1719.7 About the Authors 1729.7.1 Analyst 1729.7.2 Therapy Director 1729.7.3 Epidemiologist 1729.7.4 Global Head of Healthcare 1739.8 About GlobalData 1749.9 Disclaimer 174

List Of Tables in Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023 [Published by Global Data]

1.1 List of Tables

Table 1: Definition of the Classes of Myeloma 15

Table 2: Staging Systems for Multiple Myeloma 17

Table 3: IMWG Uniform Response Criteria for Multiple Myeloma: Response 18

Table 4: IMWG Uniform Response Criteria for Multiple Myeloma: Progression 18

Table 5: Symptoms of Multiple Myeloma 19

Table 6: Median Survival for Each Stage at Diagnosis of Multiple Myeloma 20

Table 7: Potential Diagnostic Markers that Predict Two-Year Disease Progression 21

Table 8: Summary of Prevalence and Clinical Outcomes of Translocations in Multiple Myeloma 21

Table 9: Treatment Guidelines for Multiple Myeloma 25

Table 10: Definition of the Classes of Myeloma 26

Table 11: Most Prescribed Drugs for Multiple Myeloma by Class in the Global Markets, 2014 31

Table 12: Most-Prescribed Drugs for Multiple Myeloma by Segment in the Global Markets, 2013 32

Table 13: Country Profile - France 34

Table 14: Country Profile - Germany 37

Table 15: Country Profile - Italy 39

Table 31: Country Profile - Spain 42

Table 17: Country Profile - UK 45

Table 18: Product Profile - Velcade 48

Table 19: Results from the Pivotal Phase III APEX Trial for Velcade 50

Table 20: Results from the Pivotal Phase III VISTA Trial for Velcade 51

Table 21 Results from the Subcutaneous versus Intravenous Velcade Phase III trial 51

Table 22: Common Grade 3 and 4 Adverse Events from Velcade Pivotal Clinical Trials 52

Table 23: Velcade SWOT Analysis, 2015 53

Table 24: Global Sales Forecast (\$m) for Velcade, 2013-2023 53

Table 25: Product Profile - Kyprolis 55

Table 26 Summary of Phase III Pivotal Trial Results for Kyprolis 58

Table 27: Summary of Phase II Clinical Trial Efficacy Data for Kyprolis 59

Table 28 Summary of Adverse Events from Key Phase III Pivotal Trials for Kyprolis	60
Table 29: Kyprolis SWOT Analysis, 2015	61
Table 30: Global Sales Forecasts (\$m) for Kyprolis, 2013-2023	62
Table 31: Product Profile - Revlimid	63
Table 32 Summary of Phase III Pivotal Trial Results for Revlimid in NDMM Patients	65
Table 33 Summary of Phase III Pivotal Trial Results for Revlimid in RRMM Patients	66
Table 34: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Revlimid	67
Table 35: Revlimid SWOT Analysis, 2015	68
Table 36: Global Sales Forecast (\$m) for Revlimid, 2013-2023	68
Table 37: Product Profile - Pomalyst	69
Table 38: Summary of PFS, OS, and ORR from Phase II Trial Data for Pomalyst	71
Table 39: Summary of Phase III Trial Data for Pomalyst	72
Table 40: Pomalyst SWOT Analysis, 2015	73
Table 41: Global Sales Forecasts (\$m) for Pomalyst, 2013-2023	73
Table 42: Summary of Other Therapeutic Classes, 2015	74
Table 43: Pipeline Product Profile - Farydak	83
Table 44: Summary of the Phase III PANORAMA 1 Trial of Farydak	86
Table 45: Summary of the Phase III PANORAMA 1 Trial of Farydak in Patients Who Received at Least Two Prior Lines of Therapy (Including Velcade and an IMiD)	86
Table 46: Summary of the Phase II PANORAMA 2 Trial of Farydak	87
Table 47: Grade 3-4 Adverse Events in the Phase III PANORAMA 1 Trial of Farydak	87
Table 48: Farydak SWOT Analysis, 2015	89
Table 49: Global Sales Forecast (\$m) for Farydak, 2013-2023	89
Table 50: Pipeline Product Profile - Ixazomib	90
Table 51: Response Results from the Phase II Study of Ixazomib	92
Table 52: Ixazomib SWOT Analysis, 2015	93
Table 53: Global Sales Forecast (\$m) for Ixazomib, 2013-2023	94
Table 54: Pipeline Product Profile - Empliciti	95
Table 55: Summary of the Phase III ELOQUENT 2 trial of Empliciti	97
Table 56: Efficacy Results from the Phase II Study of Empliciti with Velcade and Dexamethasone	98
Table 57: Empliciti SWOT Analysis, 2015	99

Table 58: Global Sales Forecast (\$m) for Empliciti, 2013-2023	99
Table 59: Pipeline Product Profile - Daratumumab	100
Table 60: Response Results from the Phase II Study of Daratumumab	102
Table 61: Daratumumab SWOT Analysis, 2015	104
Table 62: Global Sales Forecast (\$m) for Ddaratumumab, 2013-2023	104
Table 63: Pipeline Product Profile - Aplidin	105
Table 64: Summary of Phase II Clinical Trial Results for Aplidin	107
Table 65: Summary of Grade 3 and 4 Adverse Events of Aplidin	107
Table 66: Aplidin SWOT Analysis, 2015	108
Table 67: Global Sales Forecast (\$m) for Aplidin, 2013-2023	108
Table 68: Summary of Efficacy Data from the Phase Ib/II Clinical Trial of Oprozomib	110
Table 69: Summary of the Phase I Efficacy Results of SAR650984	111
Table 70: Summary of the Phase I Efficacy Results of Evofosfamide	113
Table 71: 5EU Sales Forecast, Multiple Myeloma, 2013-2023 (\$m)	115
Table 72: Key Events Impacting Sales for Multiple Myeloma in the 5EU, 2013-2023	119
Table 73: 5EU Multiple Myeloma - Drivers and Barriers, 2013-2023	119
Table 74: 5EU Multiple Myeloma - Barriers, 2013-2023	121
Table 75: Multiple Myeloma Diagnosed Incidence, 2013-2023	151
Table 76: Multiple Myeloma Drugs and Pipeline agents, Launch Dates	152
Table 77: Multiple Myeloma Drugs and Pipeline agents, Anticipated Patent Expiries	153
Table 78: Average Cost of Therapy for Velcade	155
Table 79: Average Duration of Treatment (Weeks) for Velcade	155
Table 80: Average Cost of Therapy for Kyprolis (\$)	157
Table 81: Average Duration of Treatment (Weeks) for Kyprolis	157
Table 82: Average Cost of Therapy for Revlimid (\$)	158
Table 83: Average Duration of Treatment (Weeks) for Revlimid	159
Table 84: Average Cost of Therapy for Pomalyst/Imnovid (\$)	160
Table 85 Average Duration of Treatment (Weeks) for Pomalyst/Imnovid	160
Table 86: Average Cost of Therapy for Farydak (\$)	161
Table 87: Duration of Treatment (Weeks) for Farydak	162
Table 88: Average Cost of Therapy for Ixazomib (\$)	163

Table 89: Duration of Treatment (Weeks) for Ixazomib 163

Table 90: Average Cost of Therapy for Empliciti (\$) 164

Table 91: Duration of Treatment (Weeks) for Empliciti 165

Table 92: Average Cost of Therapy for Daratumumab (\$) 166

Table 93: Duration of Treatment (Weeks) for Daratumumab 167

Table 94: Average Cost of Therapy for Daratumumab (\$) 168

Table 95: Duration of Treatment (Weeks) for Daratumumab 168

Table 96: Numbers of Prescribers Surveyed in Each Country 171

List Of Figures, Charts and Diagrams in Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023 [Published by Global Data]

1.2 List of Figures

Figure 1: SCT-Eligible Typical Patient Journey 27

Figure 2: Non-SCT-Eligible Typical Patient Journey 29

Figure 3: Velcade's Phase III Development in Multiple Myeloma 49

Figure 4: Kyprolis's Phase III Development in Multiple Myeloma 56

Figure 5: Revlimid's Phase III Development in Multiple Myeloma 63

Figure 6: Pomalyst/Imnovid's Phase III Development in Multiple Myeloma 70

Figure 7: Farydak's Development in Multiple Myeloma 85

Figure 8: Dosing Schedule for Farydak 88

Figure 9: Ixazomib's Development in Multiple Myeloma 91

Figure 10: Empliciti's Development in Multiple Myeloma 95

Figure 11: Daratumumab's Development in Multiple Myeloma 102

Figure 12: Annual 5EU Sales for Multiple Myeloma by Region, 2013-2023 116

Figure 13: Annual 5EU Sales for Multiple Myeloma by Drug, 2013-2023 117

Figure 14: 5EU Sales for Multiple Myeloma by Drug, 2013 and 2023 118

How to Buy...

Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023 [Published by Global Data]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/27219>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$6995** | Single User Price
- \$13990** | Site License Price
- \$20985** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.